post

I: Vancomycin & the Nephrocidal Maniacs

Vancomycin was first isolated in 1953 by Edmund Kornfeld from a soil sample collected from the jungles of Borneo by a missionary. It is produced by the soil bacterium Amycolatopsis orientalis. It was first licensed for use in patients with penicillin resistant Staph infections in 1958. Yes, vancomycin has been around longer than the Beatles! […]

post

CREDENCE Trial PODCAST: Can-I-get-a-flozin?

The CREDENCE trial was published in the NEJM last month and it has made some waves in the world of diabetes management. The headlines state that this SGLT2 drug can reduce the progression of diabetic nephropathy. That is big news indeed. So, what do I think about this new data for a drug that had […]

post

First10EM Journal Club: February 2019

Welcome to another edition of the Broomedocs/ First10EM podcast. This month Justin and I serve up a selection of serious and seriously unusual papers. Key learning points: sharks are safe, The NEJM is dangerous and you just may be able to outrun Death. As always – the links to the full text PDFs and into […]

post

Funeral Falldown

So here is a quick case for the sake of looking at a new paper in context. Mrs B is a 65 year old woman who has been brought in by ambulance from the local funeral home… no she is not dead. She was just at the home to view the cremation of her sister […]

post

VTE Risk and Prophylaxis: Devil in the Details

VTE is a problem – there is definitely a risk of hospitalized patients acquiring and either dying or developing complications from VTE. The problem is that “hospitalized patients” includes very heterogeneous groups of patients.  We know that the higher risk groups DO benefit from appropriate VTE prophylaxis: Orthopaedic surgical patients General and gynaecological surgery Oncological […]